Funding will strengthen the subsidiary ExoXpert(R), the exosome specialist CDMO, also supporting the first EMA approved MSC-derived exosome clinical trial, and the ongoing development of the ExoPulse(TM) platform.

Applied Biophysics Forum promises real-world data from nucleic acid drug delivery researchers.

The IntelliXcap™ Automated Septum Cap Decapper/Recapper from Azenta Life Sciences is a precision tube decapping / recapping instrument for use within high-throughput environments such as in biobanking.

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes.

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) has announced the grand opening of its new cGMP mRNA manufacturing facility.

Partnership endorses mission to facilitate career progression and support life science industry growth.

In a significant stride towards advancing nanoparticle drug delivery manufacturing technology, German pharmatech company, leon-nanodrugs GmbH (LEON), proudly announces a pioneering technical evaluation by CMAC, University of Strathclyde.

Access to compound collection enables greater flexibility and efficiencies in screening and target identification.

The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma